Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 14/20 | 0.47 |
| ▸ | TNF | P01375 | 4/20 | 0.47 |
| ▸ | BTK | Q06187 | 4/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24949799 | 1.00 | IRAK4 (0.47) | IRAK4TNFBTKKDM1AMAOB | |
| SCHEMBL24950194 | 0.91 | BTK (0.46) | IRAK4TNFBTK | |
| SCHEMBL30194545 | 0.89 | BTK (0.45) | IRAK4TNFBTKKDM1AMAOB | |
| SCHEMBL24950192 | 0.89 | BTK (0.45) | IRAK4TNFBTKKDM1AMAOB | |
| SCHEMBL23301590 | 0.89 | BTK (0.45) | IRAK4TNFBTKKDM1AMAOB | |
| SCHEMBL24950101 | 0.89 | BTK (0.45) | IRAK4TNFBTKKDM1AMAOB | |
| SCHEMBL31678598 | 0.87 | IRAK4 (0.48) | IRAK4TNF | |
| SCHEMBL29492883 | 0.85 | BTK (0.46) | IRAK4TNFBTKKDM1AMAOB | |
| SCHEMBL30578524 | 0.85 | BTK (0.46) | IRAK4TNFBTKKDM1AMAOB | |
| SCHEMBL24950100 | 0.85 | CNR1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014742-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014742-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 | SIK2, SIK1, SIK3 | IRAK4 518/4885TNF 2706/4885BTK 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.